International Journal of Cancer Management

Published by: Kowsar

Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles (SLNs)

Hamed Hajipour 1 , Hamed Hamishehkar 2 , Mohammad Rahmati-yamchi 3 , Dariush Shanehbandi 4 , Saeed Nazari Soltan Ahmad 1 and Akbar Hasani 2 , *
Authors Information
1 Student Research Committee and Department of Biochemistry and Clinical Laboratories, Faculty of Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
2 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Article information
  • International Journal of Cancer Management: January 2018, 11 (1); e9402
  • Published Online: January 31, 2018
  • Article Type: Research Article
  • Received: October 18, 2016
  • Revised: February 20, 2017
  • Accepted: January 24, 2018
  • DOI: 10.5812/ijcm.9402

To Cite: Hajipour H, Hamishehkar H, Rahmati-yamchi M, Shanehbandi D, Nazari Soltan Ahmad S, et al. Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles (SLNs), Int J Cancer Manag. 2018 ; 11(1):e9402. doi: 10.5812/ijcm.9402.

Abstract
Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107. [PubMed: 21296855].
  • 2. Chiam K, Ricciardelli C, Bianco-Miotto T. Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett. 2014;342(2):248-56. doi: 10.1016/j.canlet.2012.02.011. [PubMed: 22391123].
  • 3. Häkkinen SH, Kärenlampi SO, Mykkänen HM, Heinonen IM, Törrönen AR. Ellagic acid content in berries: Influence of domestic processing and storage. Europ Food Res Technol. 2000;212(1):75-80. doi: 10.1007/s002170000184.
  • 4. Vanella L, Barbagallo I, Acquaviva R, Di Giacomo C, Cardile V, Abraham NG, et al. Ellagic acid: cytodifferentiating and antiproliferative effects in human prostatic cancer cell lines. Curr Pharm Des. 2013;19(15):2728-36. [PubMed: 23092326].
  • 5. Vanella L, Di Giacomo C, Acquaviva R, Barbagallo I, Li Volti G, Cardile V, et al. Effects of ellagic Acid on angiogenic factors in prostate cancer cells. Cancers (Basel). 2013;5(2):726-38. doi: 10.3390/cancers5020726. [PubMed: 24216999].
  • 6. Li TM, Chen GW, Su CC, Lin JG, Yeh CC, Cheng KC, et al. Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res. 2005;25(2A):971-9. [PubMed: 15868936].
  • 7. Larrosa M, Tomas-Barberan FA, Espin JC. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem. 2006;17(9):611-25. doi: 10.1016/j.jnutbio.2005.09.004. [PubMed: 16426830].
  • 8. Losso JN, Bansode RR, Trappey A2, Bawadi HA, Truax R. In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem. 2004;15(11):672-8. doi: 10.1016/j.jnutbio.2004.06.004. [PubMed: 15590271].
  • 9. Bala I, Bhardwaj V, Hariharan S, Kumar MN. Analytical methods for assay of ellagic acid and its solubility studies. J Pharm Biomed Anal. 2006;40(1):206-10. doi: 10.1016/j.jpba.2005.07.006. [PubMed: 16111850].
  • 10. Murugan V, Mukherjee K, Maiti K, Mukherjee PK. Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. J Agric Food Chem. 2009;57(11):4559-65. doi: 10.1021/jf8037105. [PubMed: 19449806].
  • 11. Pandey R, Ahmad Z, Sharma S, Khuller GK. Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm. 2005;301(1-2):268-76. doi: 10.1016/j.ijpharm.2005.05.027. [PubMed: 16023808].
  • 12. Kakran M, Sahoo NG, Li L. Dissolution enhancement of quercetin through nanofabrication, complexation, and solid dispersion. Colloids Surf B Biointerfaces. 2011;88(1):121-30. doi: 10.1016/j.colsurfb.2011.06.020. [PubMed: 21764266].
  • 13. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-77. [PubMed: 10840199].
  • 14. Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363(1-2):132-8. doi: 10.1016/j.ijpharm.2008.06.028. [PubMed: 18657601].
  • 15. Garud A, Singh D, Garud N. Solid lipid nanoparticles (SLN): Method, characterization and applications. Int Current Pharmaceutical J. 2012;1(11):384-93.
  • 16. Danhier F, Danhier P, De Saedeleer CJ, Fruytier AC, Schleich N, des Rieux A, et al. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. Int J Pharm. 2015;479(2):399-407. doi: 10.1016/j.ijpharm.2015.01.009. [PubMed: 25578367].
  • 17. Ngamcherdtrakul W, Morry J, Gu S, Castro DJ, Goodyear SM, Sangvanich T, et al. Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer. Adv Funct Mater. 2015;25(18):2646-59. doi: 10.1002/adfm.201404629. [PubMed: 26097445].
  • 18. Amiji MM. Nanotechnology for cancer therapy. CRC press; 2006.
  • 19. Liu Y, Jie X, Guo Y, Zhang X, Wang J, Xue C. Green Synthesis of Oxovanadium(IV)/chitosan Nanocomposites and Its Ameliorative Effect on Hyperglycemia, Insulin Resistance, and Oxidative Stress. Biol Trace Elem Res. 2016;169(2):310-9. doi: 10.1007/s12011-015-0420-6. [PubMed: 26144273].
  • 20. Kathe N, Henriksen B, Chauhan H. Physicochemical characterization techniques for solid lipid nanoparticles: principles and limitations. Drug Dev Ind Pharm. 2014;40(12):1565-75. doi: 10.3109/03639045.2014.909840. [PubMed: 24766553].
  • 21. Li B, Harich K, Wegiel L, Taylor LS, Edgar KJ. Stability and solubility enhancement of ellagic acid in cellulose ester solid dispersions. Carbohydr Polym. 2013;92(2):1443-50. doi: 10.1016/j.carbpol.2012.10.051. [PubMed: 23399175].
  • 22. Sonaje K, Italia JL, Sharma G, Bhardwaj V, Tikoo K, Kumar MN. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats. Pharm Res. 2007;24(5):899-908. doi: 10.1007/s11095-006-9207-y. [PubMed: 17377747].
  • 23. Ezzati Nazhad Dolatabadi J, Hamishehkar H, Eskandani M, Valizadeh H. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2014;117:21-8. doi: 10.1016/j.colsurfb.2014.01.055. [PubMed: 24607519].
  • 24. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430(1-2):216-27. doi: 10.1016/j.ijpharm.2012.03.032. [PubMed: 22465548].
  • 25. Hamishehkar H, Shokri J, Fallahi S, Jahangiri A, Ghanbarzadeh S, Kouhsoltani M. Histopathological evaluation of caffeine-loaded solid lipid nanoparticles in efficient treatment of cellulite. Drug Dev Ind Pharm. 2015;41(10):1640-6. doi: 10.3109/03639045.2014.980426. [PubMed: 25382163].
  • 26. Arulmozhi V, Pandian K, Mirunalini S. Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB). Colloids Surf B Biointerfaces. 2013;110:313-20. doi: 10.1016/j.colsurfb.2013.03.039. [PubMed: 23732810].
  • 27. Eskandani M, Nazemiyeh H. Self-reporter shikonin-Act-loaded solid lipid nanoparticle: formulation, physicochemical characterization and geno/cytotoxicity evaluation. Eur J Pharm Sci. 2014;59:49-57. doi: 10.1016/j.ejps.2014.04.009. [PubMed: 24768857].
  • 28. Wang Y, Zhu L, Dong Z, Xie S, Chen X, Lu M, et al. Preparation and stability study of norfloxacin-loaded solid lipid nanoparticle suspensions. Colloids Surf B Biointerfaces. 2012;98:105-11. doi: 10.1016/j.colsurfb.2012.05.006. [PubMed: 22659379].
  • 29. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):1397-421. doi: 10.1016/j.bcp.2006.02.009. [PubMed: 16563357].
  • 30. Malik A, Afaq S, Shahid M, Akhtar K, Assiri A. Influence of ellagic acid on prostate cancer cell proliferation: a caspase-dependent pathway. Asian Pac J Trop Med. 2011;4(7):550-5. doi: 10.1016/S1995-7645(11)60144-2. [PubMed: 21803307].
  • 31. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta. 2004;1644(2-3):229-49. doi: 10.1016/j.bbamcr.2003.08.009. [PubMed: 14996506].
  • 32. Mbazima VG, Mokgotho MP, February F, Rees DJG, Mampuru L. Alteration of Bax-to-Bcl-2 ratio modulates the anticancer activity of methanolic extract of Commelina benghalensis (Commelinaceae) in Jurkat T cells. African J Biotechnol. 2008;7(20).
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments